Viewing Study NCT03350295


Ignite Creation Date: 2025-12-24 @ 2:13 PM
Ignite Modification Date: 2026-02-22 @ 6:44 PM
Study NCT ID: NCT03350295
Status: COMPLETED
Last Update Posted: 2019-12-12
First Post: 2017-11-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
Sponsor: Bayer
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module